Clovis Oncology Inc. (NASDAQ: CLVS) stock closed at 1.7 per share at the end of the most recent trading day (a -2.3% change compared to the prior day closing price) with a volume of 26.45M shares and market capitalization of 244.59M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Clovis Oncology Inc. CEO is Patrick J. Mahaffy.

The one-year performance of Clovis Oncology Inc. stock is -72.34%, while year-to-date (YTD) performance is -37.27%. CLVS stock has a five-year performance of -98.21%. Its 52-week range is between 0.581 and 6.65, which gives CLVS stock a 52-week price range ratio of 18.44%

Clovis Oncology Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 7.70, a price-to-sale (PS) ratio of 0.69, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -53.29%, a ROC of -18.45% and a ROE of 100.94%. The company’s profit margin is -%, its EBITDA margin is -150.30%, and its revenue ttm is $144.95 Million , which makes it $1.01 revenue per share.

Of the last four earnings reports from Clovis Oncology Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Clovis Oncology Inc.’s next earnings report date is 03rd Aug 2022.

The consensus rating of Wall Street analysts for Clovis Oncology Inc. is Hold (3.33), with a target price of $3, which is +76.47% compared to the current price. The earnings rating for Clovis Oncology Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Clovis Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Clovis Oncology Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.72, ATR14 : 0.26, CCI20 : 173.42, Chaikin Money Flow : -0.24, MACD : 0.13, Money Flow Index : 84.87, ROC : 133.93, RSI : 69.48, STOCH (14,3) : 61.52, STOCH RSI : 0.88, UO : 49.71, Williams %R : -38.48), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Clovis Oncology Inc. in the last 12-months were: Daniel W. Muehl (Option Excercise at a value of $0), Daniel W. Muehl (Sold 25 468 shares of value $62 465 ), Gillian C. Ivers-Read (Option Excercise at a value of $0), Gillian C. Ivers-Read (Sold 25 259 shares of value $56 800 ), Lindsey Rolfe (Option Excercise at a value of $0), Lindsey Rolfe (Sold 24 253 shares of value $59 471 ), Paul Edward Gross (Option Excercise at a value of $0), Paul Edward Gross (Sold 27 871 shares of value $64 008 ), Thomas C. Harding (Option Excercise at a value of $0), Thomas C. Harding (Sold 13 654 shares of value $31 535 )